Progress tracks

Can OX40 agonists produce a clinically demonstrated benefit for cancer patients, alone or in combination with other immunotherapies?

Main bottleneck: Current evidence describes patent activity and reviews of development challenges and clinical applications, but does not establish reproducible clinical benefit. Translating the proposed approaches into convincing patient evidence remains unresolved.

Can checkpoint immunotherapy provide safe, meaningful benefit for people with lung cancer and poor performance status?

Main bottleneck: The bounded evidence includes a three-patient case series and a planned systematic review and meta-analysis; it does not yet establish how consistently immunotherapy works or how safe it is for this group.

Can lymphaticovenous anastomosis safely and reliably improve Alzheimer’s disease outcomes, and what mechanism would explain any benefit?

Main bottleneck: Current evidence does not establish clinical benefit or explain the mechanism: it lists an efficacy-and-mechanism trial and a planned narrative review, but no reported results or confirmatory evidence.

Can senolytic treatment produce cognitive benefits that replicate across sexes and disease models?

Main bottleneck: The bounded evidence is limited to mouse studies, and the reported result differs by sex in one model. Replication across models and sexes remains unresolved.

Can senolytic drugs reduce seizure severity across distinct epilepsy settings, including when treatment begins after seizures develop?

Main bottleneck: The two reports address different epilepsy settings and treatment circumstances, leaving the durability, safety, and applicability of the benefits after seizure onset unresolved.

Can gene delivery produce lasting functional improvements in creatine transporter deficiency beyond raising cellular creatine levels and partially correcting behavioural changes?

Main bottleneck: The bounded evidence does not establish that increased creatine in patient fibroblasts and the reported animal improvements translate into durable, comprehensive functional recovery.

Can automated satellite tasking adapt to changing mission priorities while keeping schedules within spacecraft constraints and operational rules?

Main bottleneck: Current evidence does not establish whether constraint enforcement remains reliable as scheduling preferences change across heterogeneous satellites, or whether scheduling and ground-side policy checks work together.

Can oncolytic viruses strengthen antitumor immunity enough to improve lung cancer treatment, including when combined with PD-L1 therapy?

Main bottleneck: Current evidence does not establish whether the reported immune activation and combination efficacy translate into reproducible benefit for people with lung cancer.

Can self-healing conductors and polymer semiconductors restore electrical function after damage while remaining stretchable enough for wearable electronics?

Main bottleneck: The unresolved test is whether healing reliably restores electrical performance as well as mechanical integrity through repeated damage and stretching; Current evidence does not establish that durability.

Can melatonin treatment provide lasting benefits for memory and daily functioning in people with Alzheimer’s disease?

Main bottleneck: Current evidence identifies reviews and trials, including a three-month study of cerebellar structure and blood biomarkers, but does not establish whether melatonin produces sustained clinical benefits.